Pipeline
Turning Somatic Insights into Breakthrough Medicines
With only a fraction of today’s biopharma pipeline focused on truly novel drug targets, somatic genomics offers a powerful new way forward, shining a light on discoveries that could fuel the next wave of medical breakthroughs. Our science is not constrained by disease, cell type or even desired drug modality, making it a potentially universal method to identify novel, genetically-validated drug targets.
Any disease, any tissue, any cell type
We have validated our approach across multiple therapeutic areas including autoimmune disease, cardiometabolic disease, oncology, rare disease and many others. Our current internal focus is on developing drug candidates in autoimmune disease, and we have partnerships in cardiovascular, respiratory, liver diseases and IBD.
Publications
Somatic Genomics has been published in high-impact journals across a broad range of therapeutic areas.